Corvus Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Selling, General & Admin	6.88	8.1	9.52	11.93	10.88	10.64	10.22	7.62	2.42	0.12
Research & Development	16.53	24.47	29.12	31.83	37.98	38.59	46.31	29.36	11.35	0.04
Other Operating Expenses	0	-0.02	0	0	0	0	0	0	0	0
Operating Expenses	23.41	32.54	38.63	43.76	48.85	49.22	56.52	36.98	13.77	0.16
Operating Income	-23.41	-32.54	-38.63	-43.76	-48.85	-49.22	-56.52	-36.98	-13.77	-0.16
Other Expense / Income	3.62	8.76	4.61	-37.77	-2.18	-2.28	-0.86	-0.6	17.57	-
Pretax Income	-27.03	-41.31	-43.24	-6	-46.67	-46.94	-55.66	-36.38	-31.34	-0.16
Net Income	-27.03	-41.31	-43.24	-6	-46.67	-46.94	-55.66	-36.38	-31.34	-0.16
Shares Outstanding (Basic)	48	47	42	29	29	28	20	15	0	0
Shares Outstanding (Diluted)	48	47	42	29	29	28	20	15	0	0
Shares Change	3.16%	11.23%	41.98%	0.44%	6.69%	34.27%	32.85%	4027.48%	119.43%	-
EPS (Basic)	-0.56	-0.89	-1.03	-0.20	-1.59	-1.71	-2.72	-2.36	-83.86	-0.95
EPS (Diluted)	-0.56	-0.89	-1.03	-0.20	-1.59	-1.71	-2.72	-2.36	-83.86	-0.95
Free Cash Flow	-23.97	-27.27	-36.72	-34.85	-37.35	-41.34	-46.48	-30.06	-13.08	-0.1
Free Cash Flow Per Share	-0.50	-0.59	-0.88	-1.18	-1.27	-1.50	-2.27	-1.95	-34.99	-0.56
EBITDA	-26.88	-40.94	-42.78	-5.36	-45.93	-46.09	-54.82	-35.78	-31.19	-0.16
Depreciation & Amortization	0.15	0.37	0.46	0.63	0.74	0.85	0.84	0.59	0.15	0
EBIT	-27.03	-41.31	-43.24	-6	-46.67	-46.94	-55.66	-36.38	-31.34	-0.16

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).